Tesamorelin
FDA ApprovedTesamorelin
- Category
- Growth Hormone
- Aliases
- Egrifta, Egrifta SV
- Administration
- Subcutaneous injection (once daily)
Overview
Tesamorelin is a synthetic GHRH analog and one of the few FDA-approved compounds among the growth-hormone-stimulating peptides discussed on this site, approved specifically to reduce excess visceral abdominal fat in patients with HIV-associated lipodystrophy. It's also the featured FDA-approved compound in the Trinity Stack.
Treatments studied
Treatment categories
HIV-associated lipodystrophy (FDA approved)
Its only FDA-approved use, specifically shown to reduce the visceral fat redistribution associated with this condition.
Visceral fat reduction (off-label interest)
Growth hormone stimulation selectively targets visceral fat more than fat elsewhere in the body.